Combination of Trastuzumab, Pertuzumab and Docetaxel as Neoadjuvant Therapy in the Management of Previously Untreated HER2-Positive Early, Locally Advanced and Inflammatory Breast Cancer


Combination of Trastuzumab, Pertuzumab and Docetaxel as Neoadjuvant Therapy in the Management of Previously Untreated HER2-Positive Early, Locally Advanced and Inflammatory Breast Cancer
Slides from a presentation at SABCS 2010 and comments from a recent interview with Luca Gianni, MD (12/10/10)

Gianni L et al. Neoadjuvant pertuzumab (P) and trastuzumab (H): Antitumor and safety analysis of a randomized phase II study (‘NeoSphere’). San Antonio Breast Cancer Symposium 2010;Abstract S3-2.

Dr Gianni is Director of Medical Oncology 1 in the Department of Medical Oncology at the Istituto Nazionale Tumori di Milano in Milan, Italy.